Literature DB >> 21864512

Specific and prolonged proteasome inhibition dictates apoptosis induction by marizomib and its analogs.

Claudia P Miller1, Christa A Manton, Randal Hale, LaKeisha Debose, Venkat R Macherla, Barbara C Potts, Michael A Palladino, Joya Chandra.   

Abstract

Marizomib (NPI-0052) is a naturally derived irreversible proteasome inhibitor that potently induces apoptosis via a caspase-8 and ROS-dependent mechanism in leukemia cells. We aim to understand the relationship between the irreversible inhibition of the proteasome and induction of cell death in leukemia cells by using analogs of marizomib that display reversible and irreversible properties. We highlight the importance of sustained inhibition of at least two proteasome activities as being key permissive events for the induction of the apoptotic process in leukemia cells. These data provide the basis for the development of new approaches to generate more effective anti-proteasome therapies. Published by Elsevier Ireland Ltd.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21864512      PMCID： PMC3186881          DOI： 10.1016/j.cbi.2011.08.005

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN： 0009-2797            Impact factor:   5.192


  15 in total

1.  Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora.

Authors:  Robert H Feling; Greg O Buchanan; Tracy J Mincer; Christopher A Kauffman; Paul R Jensen; William Fenical
Journal:  Angew Chem Int Ed Engl       Date:  2003-01-20       Impact factor: 15.336

Review 2.  20S proteasome and its inhibitors: crystallographic knowledge for drug development.

Authors:  Ljudmila Borissenko; Michael Groll
Journal:  Chem Rev       Date:  2007-02-23       Impact factor: 60.622

3.  Mechanistic studies on the inactivation of the proteasome by lactacystin in cultured cells.

Authors:  L R Dick; A A Cruikshank; A T Destree; L Grenier; T A McCormack; F D Melandri; S L Nunes; V J Palombella; L A Parent; L Plamondon; R L Stein
Journal:  J Biol Chem       Date:  1997-01-03       Impact factor: 5.157

4.  The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia.

Authors:  Stacey Ruiz; Yelena Krupnik; Michael Keating; Joya Chandra; Michael Palladino; David McConkey
Journal:  Mol Cancer Ther       Date:  2006-07       Impact factor: 6.261

5.  Increasing expression of heme oxygenase-1 by proteasome inhibition protects astrocytes from heme-mediated oxidative injury.

Authors:  Jing Chen; Raymond F Regan
Journal:  Curr Neurovasc Res       Date:  2005-07       Impact factor: 1.990

6.  Crystal structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding.

Authors:  Michael Groll; Robert Huber; Barbara C M Potts
Journal:  J Am Chem Soc       Date:  2006-04-19       Impact factor: 15.419

7.  Elevation of heme oxygenase-1 by proteasome inhibition affords dopaminergic neuroprotection.

Authors:  Noriyuki Yamamoto; Yasuhiko Izumi; Takaaki Matsuo; Seiko Wakita; Toshiaki Kume; Yuki Takada-Takatori; Hideyuki Sawada; Akinori Akaike
Journal:  J Neurosci Res       Date:  2010-07       Impact factor: 4.164

8.  Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells.

Authors:  Claudia P Miller; Sharmistha Rudra; Michael J Keating; William G Wierda; Michael Palladino; Joya Chandra
Journal:  Blood       Date:  2009-01-30       Impact factor: 22.113

9.  Proteasome inhibitors up-regulate haem oxygenase-1 gene expression: requirement of p38 MAPK (mitogen-activated protein kinase) activation but not of NF-kappaB (nuclear factor kappaB) inhibition.

Authors:  Wen-Tung Wu; Kwan-Hwa Chi; Feng-Ming Ho; Wei-Chia Tsao; Wan-Wan Lin
Journal:  Biochem J       Date:  2004-05-01       Impact factor: 3.857

10.  Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells.

Authors:  Joya Chandra; Jennifer Hackbarth; Son Le; David Loegering; Nancy Bone; Laura M Bruzek; Ven L Narayanan; Alex A Adjei; Neil E Kay; Ayalew Tefferi; Judith E Karp; Edward A Sausville; Scott H Kaufmann
Journal:  Blood       Date:  2003-08-14       Impact factor: 22.113
View more
  5 in total

1.  Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier.

Authors:  Kaijun Di; G Kenneth Lloyd; Vivek Abraham; Ann MacLaren; Francis J Burrows; Annick Desjardins; Mohit Trikha; Daniela A Bota
Journal:  Neuro Oncol       Date:  2015-12-17       Impact factor: 12.300

Review 2.  Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma.

Authors:  Lenka Kubiczkova; Ludek Pour; Lenka Sedlarikova; Roman Hajek; Sabina Sevcikova
Journal:  J Cell Mol Med       Date:  2014-04-08       Impact factor: 5.310

3.  Nicotiana benthamiana as a Transient Expression Host to Produce Auxin Analogs.

Authors:  Katharine Davis; Danai S Gkotsi; Duncan R M Smith; Rebecca J M Goss; Lorenzo Caputi; Sarah E O'Connor
Journal:  Front Plant Sci       Date:  2020-11-20       Impact factor: 5.753

4.  Combined treatment of marizomib and cisplatin modulates cervical cancer growth and invasion and enhances antitumor potential in vitro and in vivo.

Authors:  Ziruizhuo Zhang; Songcheng Zhang; Bingjie Lin; Qixin Wang; Xiaojing Nie; Yonghua Shi
Journal:  Front Oncol       Date:  2022-08-30       Impact factor: 5.738

Review 5.  Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling.

Authors:  Fabrizio Accardi; Denise Toscani; Marina Bolzoni; Benedetta Dalla Palma; Franco Aversa; Nicola Giuliani
Journal:  Biomed Res Int       Date:  2015-10-22       Impact factor: 3.411
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.